HHM Wealth Advisors LLC Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 2nd, 2023

HHM Wealth Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 13.5% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,710 shares of the company’s stock after buying an additional 441 shares during the quarter. HHM Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $575,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of JNJ. Moneta Group Investment Advisors LLC raised its position in shares of Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Johnson & Johnson by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock valued at $8,456,643,000 after purchasing an additional 294,671 shares during the last quarter. Morgan Stanley raised its position in shares of Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Johnson & Johnson by 15.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after purchasing an additional 3,849,148 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $4,609,399,000. 67.57% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $168.89 on Wednesday. The company’s fifty day moving average price is $162.21 and its 200 day moving average price is $161.03. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The stock has a market capitalization of $438.90 billion, a P/E ratio of 34.19, a P/E/G ratio of 2.93 and a beta of 0.55. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. The firm had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same quarter last year, the company earned $2.59 EPS. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.76 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a $1.19 dividend. The ex-dividend date is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.82%. Johnson & Johnson’s payout ratio is currently 96.36%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,163 shares of company stock worth $7,928,856. Corporate insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several research analyst reports. Citigroup initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective for the company. StockNews.com assumed coverage on shares of Johnson & Johnson in a report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Finally, Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Eight analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $171.60.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.